So here is why I think Leo chose this particular l
Post# of 72440
Posted On: 10/02/2015 2:54:46 PM
So here is why I think Leo chose this particular law firm. It is a message that lawsuits can go both ways. Just read the PR from Rosen. They flat out said the reason shareholders were harmed was due to the Mako hit piece on SA so if the article is the reason share holders were harmed then the author and co-conspirators should be help responsible for stock manipulation. The following was e-mailed to Karinca.
Quote:Leo Ehrlich
10:33 AM
to me
Our attorney has the corporate filing by Mako Research in Ohio. Eventually the "Mako Research" or someone involved in the racket will talk and implicate the others . It always happens. Just will take some time. We've picked the right attorney's for this kind of situation.
Leo Ehrlich | CEO |
" On August 6, 2015, Seeking Alpha published an article revealing that Cellceutix misrepresented the efficacy of its drug candidates Brilacidin, Kevetrin, and Prurisol. On this news, shares of Cellceutix fell sharply during intraday trading on August 6, 2015, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Cellceutix investors. If you purchased shares of Cellceutix before August 6, 2015, please visit the firm’s website at http://rosenlegal.com/cases-689.html for more information. You may also contact Phillip Kim or Jonathan Stern of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or jstern@rosenlegal.com. "
Quote:Leo Ehrlich
10:33 AM
to me
Our attorney has the corporate filing by Mako Research in Ohio. Eventually the "Mako Research" or someone involved in the racket will talk and implicate the others . It always happens. Just will take some time. We've picked the right attorney's for this kind of situation.
Leo Ehrlich | CEO |
" On August 6, 2015, Seeking Alpha published an article revealing that Cellceutix misrepresented the efficacy of its drug candidates Brilacidin, Kevetrin, and Prurisol. On this news, shares of Cellceutix fell sharply during intraday trading on August 6, 2015, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Cellceutix investors. If you purchased shares of Cellceutix before August 6, 2015, please visit the firm’s website at http://rosenlegal.com/cases-689.html for more information. You may also contact Phillip Kim or Jonathan Stern of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or jstern@rosenlegal.com. "
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼